Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arctic Bioscience AS ( (DE:9TD) ) has shared an update.
Arctic Bioscience has announced an increase in its share capital following the conversion of debt into equity, resulting in the issuance of 96,916 new shares. This move is expected to enhance the company’s financial structure and potentially strengthen its market position, providing stakeholders with improved investment security.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company specializing in the development and commercialization of pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. The company is focused on creating HRO350, an oral drug candidate for treating mild-to-moderate psoriasis, and offers nutraceuticals globally under the ROMEGA® brand.
Average Trading Volume: 29,559
Current Market Cap: NOK98.84M
For detailed information about 9TD stock, go to TipRanks’ Stock Analysis page.